MAXALT 5mg price in UAE

Overview

Welcome to Dwaey, specifically on MAXALT 5mg Tablets page.
This medicine contains an important and useful components, as it consists of Rizatriptan (as benzoate).
MAXALT 5mg is available in the market in concentration 5mg/Tablet and in the form of Tablets.

MERCK SHARP & DOHME B.V. is the producer of MAXALT 5mg and it is imported from NETHERLANDS, The most popular alternatives of MAXALT 5mg are listed downward .

Mode Of Action

Rizatriptan is a selective serotonin (5-HT1) agonist in cranial arteries responsible for vasoconstriction and reduction of inflammation associated with antidromic neuronal transmission.

Indication

Acute migraine attacks

Precaution

Elderly; mild to moderate hepatic or renal impairment; coronary artery disease; pregnancy, lactation. May cause drowsiness. History of seizures. Ensure an interval of at least 24 hr after stopping an ergotamine compound and starting a serotonin (5-HT1) agonist. Lactation: Unknown; use with caution in breastfeeding

Side Effects

>10% Drowsiness (13-30%
dose related)
Fatigue (13-30%
dose related)
Dizziness (11-15%) 1-10% Dizziness (4-9%)
Somnolence (4-8%)
Fatigue (4-7%; dose related)
Nausea (4-6%)
Asthenia (1-5%)
Hot flashes (1-5%)
Paresthesia (3-4%)
Dry mouth (3%)
Chest pain (2-3%)
Pain/pressure in chest
neck
throat
jaw (<2%)
Headache (<2%)
Dyspnea (>1%)
Hypoesthesia (>1%)
Palpations (>1%)
Skin flushing (>1%) <1% Tachycardia
Angioedema
Wheezing
Hypertensive crisis
Bradycardia
Hallucination
Epidermal necrolysis
Hearing impairment
Arrhythmias
Myocardial infarction and coronary artery vasospasm in patients with CAD risk factors Potentially Fatal: Toxic epidermal necrolysis.

Contra indication

History of MI, peripheral vascular disease, transient ishaemic attack, ischaemic heart disease or Prinzmetal's angina; uncontrolled hypertension; basilar or hemiplegic migraine; severe hepatic or renal impairment. Adolescent <18 yr.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased serum concentrations with propranolol. Increased risk of vasospastic reactions when used with ergotamine and methysergide. Concurrent use with SSRIs may increase risk of serotonin syndrome. Potentially Fatal: Concurrent use with or within 2 wk of stopping MAOI treatment.